Potassium Channel, Two Pore Domain Subfamily K, Member 16 (TALK-1/KCNK16) is a K+ channel protein expressed in human and murine pancreas. Recent research by Vierra et al suggested a regulatory function of KCNK16 in mice for glucose-dependent β-cell second-phase insulin and δ-cell somatostatin secretion and a protective effect on fasting glycemia during 3 weeks high-fat diet (HFD). We tested the hypothesis, that deletion of KCNK16 affects body weight and glucose metabolism in vivo during prolonged HFD feeding. Therefore, we analyzed KCNK16-deficient knockout mice (KCNK16-/-) during HFD up to 21 weeks investigating body weight and composition, insulin sensitivity as well as insulin secretion. In HFD-fed KCNK16-/-, we observed a reduced body weight gain. Both, fat and lean mass were reduced and notably body-length was also significantly shorter. KCNK16-/- mice showed reduced food intake, an elevated oxygen consumption and energy expenditure. KCNK16-/- islets showed enhanced insulin secretion under glucose and GIP-1 simulation, but we did not reveal significant changes in fasting or fed plasma glucose or insulin. We found a moderate decrease in blood glucose during an ipITT. However, we did not observe an enhanced insulin sensitivity assessed by hyperinsulinemic-euglycemic clamps nor a beneficial effect of KCNK16 deficiency on the modulation of in vivo insulin secretion during hyperglycemic clamps in HFD-fed mice.

In conclusion, we observed a reduced body weight gain, but also shorter body-length in the KCNK16-deficient mouse model during prolonged HFD feeding. Notably, food intake was reduced while energy expenditure was increased.


S. Brachs: Employee; Spouse/Partner; Treamid Therapeutics GmbH. Research Support; Self; Sanofi-Aventis Deutschland GmbH. U. Schwahn: Employee; Self; Sanofi-Aventis Deutschland GmbH. K. Steinmeyer: Employee; Self; Sanofi-Aventis Deutschland GmbH. M. Schäfer: Employee; Self; Sanofi-Aventis Deutschland GmbH. J. Gassenhuber: Employee; Self; Sanofi-Aventis Deutschland GmbH. Employee; Spouse/Partner; Sanofi-Aventis Deutschland GmbH. J. Spranger: None.


Sanofi Aventis Deutschland GmbH

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.